Introduction Learning Objectives Introduction

Introduction

Watch a series of internationally renowned clinical specialists from Europe and the United States discuss key clinical data of interest from the European Society for Medical Oncology (ESMO) Breast Cancer Congress, Berlin, Germany, 2–4 May 2019.

The potential implications of these data for optimizing clinical outcomes for patients with advanced breast cancer are explored from both global and regional perspectives.

The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with breast cancer.

Learning Objectives

After watching these touchCONGRESS Expert Interviews from ESMO 2019, you should be able to:

Describe the role of CDK4/6 inhibitors in the context of the current and evolving treatment landscape for patients with HR+/HER2- advanced breast cancer
Evaluate the importance of selecting the optimal treatment based on the individual patient, and the challenges around subsequent sequencing of therapy
Summarize the importance of managing the safety profiles of CDK4/6 inhibitor therapy, and recognise the significance of the multidisciplinary team in optimizing patient outcomes and maintaining on-treatment benefits

PROFESSOR GABRIEL HORTOBAGYI

Professor Hortobagyi, Professor in the Department of Breast Medical Oncology at The University of Texas M.D. Anderson Cancer Center, provides his expert insight into key data presented at the ESMO Breast Cancer Congress 2019 and discusses what the latest developments in CDK4/6 inhibitors mean for optimizing clinical outcomes for patients with advanced breast cancer.

Clinical Spotlight

The results from the AURORA screening initiative for metastatic breast cancer have been presented. How do you think these findings will impact clinical practice, both globally and in your region?
How valuable do you think the results are from real-world assessments of CDK4/6 inhibitors? Will the findings alter how these agents are used?
What do you think will be the role for chemotherapy in patients with HR+/HER2- advanced breast cancer in the future, with the availability of CDK4/6 inhibitors?
Data on resistance to CDK4/6 inhibitors and treatment sequencing were shared. How do you interpret these for your clinical practice?
Pooled safety data for a CDK4/6 inhibitor in patients with advanced breast cancer were presented. How will these findings affect how you manage adverse events in your clinic?
Which data stood out for you at the 2019 ESMO Breast Cancer Congress and why? What are their implications for clinical practice in your region?

About PROFESSOR GABRIEL HORTOBAGYI

Gabriel Hortobagyi is Professor in the Department of Breast Medical Oncology at The University of Texas M.D. Anderson Cancer Center. His oncology career of more than 40 years has focused on clinical and translational research, teaching and mentoring the next generation of scientists, and academic leadership. He is Past President of the American Society of Clinical Oncology (ASCO) and is one of the world’s leading authorities on the management of breast cancer. Professor Hortobagyi has been the recipient of numerous prestigious awards. He has over 1100 full-length publications in peer-reviewed journals and over 140 book chapters to his credit.

Professor Hortobagyi has served on various task forces and committees of the American Society of Clinical Oncology, served on the Board of Directors, and in 2005 was elected President. He served as President of the International Society of Senology; as a board member for the International Association for Breast Cancer Research; as a member of the U.S. National Committee for the International Union Against Cancer, the National Cancer Institute’s Breast Cancer Progress Review Group, and the Integration Panel of the Breast Cancer Research Program of the Department of Defense. In addition, Professor Hortobagyi chaired the Steering Committee of the Breast Health Global Initiative, the Health Advisory Board of the Susan G. Komen Breast Cancer Foundation, the NCI’s Operational Efficiency Working Group and the Breast Cancer Steering Committee. Professor Hortobagyi was Chair of the Southwest Oncology Group Breast Committee until June 2017 and is chair of the Executive Board of Scientific Advisors of The Breast Cancer Research Foundation.

Disclosures: Served as a consultant to Novartis in the development of the BOLERO-2, MONALEESA-2 and NATALEE clinical trials.

touchCONGRESS Expert Interviews:
Advanced Breast Cancer

Touch Oncology

touchCONGRESS Expert Interviews

HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ESMO Breast Cancer Congress 2019?

Introduction

Learning Objectives

Please feedback on this touchCONGRESS Expert Interviews on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).

touchCONGRESS Expert Interviews: Advanced Breast Cancer

LOGIN or REGISTER to access this content

Introduction

Learning Objectives

Please feedback on this touchCONGRESS Expert Interviews on the following:(scale 1-5, 1 strongly disagree; 5 strongly agree).

touchCONGRESS Expert Interviews:
Advanced Breast Cancer

Please feedback on this touchCONGRESS Expert Interviews on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).